Clearmind Completes Recruitment for Alcohol Disorder Trial
The Phase I/IIa trial for CMND-100 now includes patients diagnosed with moderate-to-severe Alcohol Use Disorder.
Updated on Oct. 27, 2026 in Substance Abuse
Live Poll
Do you trust pharmaceutical companies to properly prioritize patient safety during early-stage clinical drug trials?
Clearmind Medicine has successfully finished patient recruitment for the first cohort of its Phase I/IIa clinical trial evaluating the drug CMND-100. This milestone marks the shift from testing healthy volunteers to assessing individuals diagnosed with moderate-to-severe Alcohol Use Disorder.
Why it matters
The clinical trial is designed to provide a specialized dataset regarding the safety and potential efficacy of CMND-100 in patients struggling with alcohol addiction. By observing participants for signs of reduced cravings, researchers hope to determine if this compound offers a viable treatment path for the condition.
The study evaluates CMND-100 across sequential cohorts with dosages of 80 mg and 160 mg. Clearmind Medicine currently manages its intellectual property portfolio through 19 patent families consisting of 32 granted patents.
The players
Clearmind Medicine
This biotechnology company focuses on the development of novel psychedelic-based therapeutics for the treatment of alcohol and other health disorders.
Johns Hopkins University School of Medicine
This prestigious medical institution serves as a clinical trial site for the testing of CMND-100.
Yale School of Medicine
This institution is participating as a clinical research site for the ongoing Phase I/IIa study.
Tel Aviv Sourasky Medical Center
This major Israeli hospital facility is one of the clinical trial locations for the current study.
Hadassah Medical Center
Located in Israel, this center is contributing to the research efforts as a designated trial site.
The details
The trial utilizes a sequential single-dose ascending design to monitor safety, tolerability, and pharmacokinetics at testing sites including Johns Hopkins University School of Medicine and Yale School of Medicine. Researchers are currently evaluating the participants for indications that the drug may reduce alcohol cravings.
Timeline
October 27, 2026: Clearmind Medicine officially announced the completion of patient recruitment.
The Big Picture
This development represents a critical progression in the ongoing clinical development of CMND-100 as the company advances its pipeline of potential treatments. The study follows the company's strategy to expand its pharmaceutical reach through continuous patent generation and active testing.
While CMND-100 is currently in the experimental phase, this shift toward patient testing brings the drug one step closer to potential clinical application for those suffering from alcohol addiction. Patients should note that this drug remains under investigation and is not yet available for general use.
The takeaway
The transition to testing patients with Alcohol Use Disorder is a significant milestone that moves the company closer to potential future treatment options. It serves as a reminder of the rigorous and sequential nature of clinical trials required to bring new medical compounds to the public.
Further reading
Learn more about the latest research and developments in the field of Substance Abuse.
More information
For more information on the trial design and company pipeline, visit the company official website.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you trust pharmaceutical companies to properly prioritize patient safety during early-stage clinical drug trials?
